| Author/Editor | Zver, Samo; Pretnar, Jože | |
| Title | Naše izkušnje pri zdravljenju akutne mieloblastne levkemije s kladribinom pri starejših bolnikih | |
| Translated title | Treatment of acute myeloblastic leukemia with cladribine in elderly patients - our exeperiencies | |
| Type | članek | |
| Source | Zdrav Vestn | |
| Vol. and No. | Letnik 67, št. Suppl 1 | |
| Publication year | 1998 | |
| Volume | str. I-39-42 | |
| Language | slo | |
| Abstract | Background. nucleosid analogue cladribine is a newer drug for treatment of acute leukemias. Usually is used in combination with cytosine-arabinoside in elderly patients. We present retrograde overview of elderly patients with acute myeloid leukemia trograde overview of elderly patients acute myeloid leukemia (AML), who were treated with cladribine and low doses cytosine arabinoside in Ljubljana haematologic department between 1. 1. 1996 and 1.3. 1998. Methods. During mentioned period we have treated 14 patients with cladribine and low doses cytosine-arabinoside, with median age of 72 years. 9 patients were males and 5 females. Patients recieved cladribine in dosage 0,1 mg/kg/body weight seven days and cytosine arabinoside 13 mg/m2/body surface area for fourteen days. 10/14 patients (71%) did not recive chemotherapy before treatment and 4/14 patients (29%) recieved at least one cycle of chemotherapy. During the treatment we documented neutrophyl granulocyte cell count, disapperance of blast cells from peripheral blood, number of achieved remissions of AML and complications considering chemotherapy with cladribine. Results. 4/14 patients (29%) achieved complete remission and 1/14 (7%) patients achieved partial remission of AML. Only patients who did not recieved chemotherapy before cladribrine achieved remission of AML. On average the lowest neutrophyl granulocyte cell count was day 12 after beginning of chemotherapy and the first signs of bone marrow regeneration were noticed on day 14 after completion of chemotherapy. 3/14 patients (21%) died during the treatment. We did not documented serious and long lasting side effects of cladribine and low doses cytosine-arabinoside treatment.(Abstract truncated at 2000 characters.) | |
| Summary | Izhodišča. Nukleozidni analog kladribin je novejše zdravilo za zdravljenje akutnih levkemij. Po navadi se uporablja v kombinaciji s citozin-arabinozidom pri zdravljenju starejših bolnikov. Prikazujemo retrogradni pregled zdravljenja starejših bolnikov z akutno mieloblastno levkemijo (AML), ki smo jih zdravili z kladribinom in nizkimi odmerki citozin-arabinozida na Kliničnem oddelku za hematologijo od 1. 1. 1996 do 1. 3. 1998. Metode. Z kladribinom in nizkimi odmerki citozin-arabinozida smo zdravili 14 bolnikov, 9 moških in 5 žensk. Bolniki so prejemali kladribin v odmerku 0,1 mg/kg/telesne teže sedem dni in citozinarabinozid 13 mg/m2/telesne površine štirinajst dni zapored. mediana starost bolnikov je bila 72 let. Deset od štirinajst bolnikov (71%) poprej ni bilo zdralvjenih s citostatiki, štirje od štirinajstih bolnikov (29%) pa so bili poprej že zdravljeni. Med zdravljenjem smo beležili Število nevtrofilnih granulocitov, blastnih celic v periferni krvi, število doseženih remisij bolezni in zaplete zdralvjenja s kladribinom. Rezultati. pri štirih od štirinajst bolnikov (29%) smo dosegli popolno remisijo bolezni, pri enem bolniku (7%) pa delono remisijo AML. Skupno je bilo zdravljenje uspešno pri petih od štirinajstih bolnikov (36%). Remisijo AML smo dosegli le pri poprej nezdravljenih bolnikih. Najmanjše število nevtrofilnih granulocitov smo v povprečju zasledili dvanajsti dan zdravljenja. prve znake regeneracije kostnega mozga v krvni sliki smo v povprečju beležili 14 dan po končani kemoterapiji. Trije od štirinajstih bolnikov (21%) so med zdravljenjem umrli. Resnejših zapletov in trajnih neželenih učinkov zdravljenja z kladribinom in citozin-arabinozidom nismo opazovali.(Izvleček prekinjen pri 2000 znakih.) | |
| Descriptors | LEUKEMIA, MYELOCYTIC, ACUTE CLADRIBINE AGED TREATMENT OUTCOME |